A PHASE I DOSE-ESCALATION STUDY OF CARFLIZOMIB IN PATIENTS WITH PREVIOUSLY-TREATED SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium
A PHASE 3 RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY OF DEXAMETHASONE PLUS MLN9708 OR PHYSICIAN'S CHOICE OF TREATMENT ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTO09/28/2012 - 09/27/2019 (PI)
Millennium Pharmaceuticals, Inc.
PHASE II STUDY OF THE COMBINATION BENDAMUSTINE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AL AMYLOIDOSIS09/04/2012 - 09/09/2019 (PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc.
A PHASE 1, OPEN LABEL, DOSE ESCALATION STUDY OF INTRAVENOUS ADMINISTRATION OF SINGLE AGENT NEOD001 IN SUBJECTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited
MOLECULAR IMAGING OF PRIMARY AMYLOID CARDIOMYOPATHY04/01/2017 - 03/31/2019 (Co-PI)
PI:
Frederick L. Ruberg, MDThe Brigham and Women's Hospital, Inc. NIH NHLBI5R01HL130563-02
AN OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF THE ORAL FORMULATION OF MLN9708 ADMINISTERED WEEKLY IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY LIGHT-CHAIN (AL) AMYLOIDOSIS WHO REQUIRE FURTHER04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.
A PHASE I/II TRIAL OF POMALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH AL AMYLOIDOSIS03/01/2012 - 02/28/2019 (PI)
Celgene Corporation
A PHASE II MULTI-CENTER STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION WITH POST TRANSPLANT MAINTENANCE FOR THE TREATMENT OF01/06/2016 - 01/05/2019 (Co-PI)
PI:
Robert W. Simms, MDFred Hutchinson Cancer Research Center Scleroderma Res Fdn
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNO12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.
PHASE II TRIAL OF INDUCTION THERAPY WITH BORTEZOMIB AND DEXAMETHASONE FOLLOWED BY HIGH-DOSE MELPHALAN AND STEM CELL TRANSPLANTATION IN PATIENTS WITH AL AMYLOIDOSIS04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.
Showing 10 of 14 results.
Show All Results
A RANDOMIZED, MULTICENTER, PHASE 3 STUDY COMPARING CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (CRD) VS. LENALIDOMIDE AND DEXAMETHASONE (RD) IN SUBJECTS WITH RELAPSED MULTIPLE MYELOMA
03/01/2010 - 03/09/2013 (PI)
Onyx Pharmaceuticals, Inc.
A MULTICENTERPHASE II TRIAL OF VELCADE, MELPHALAN, AND DEXAMETHASONE (V-MD) IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD
11/10/2008 - 11/09/2010 (PI)
Millennium Pharmaceuticals, Inc.
AN OPEN LABEL, PHASE 1/2 STUDY OF VELCADE (BORTEZOMIB) FOR INJECTION IN SUBJECTS WITH LIGHT CHAIN AMYLOIDOSIS
05/09/2005 - 08/31/2010 (PI)
Johnson & Johnson
RANDOMIZED, PHASE 3B STUDY OF THREE TREATMENT REGIMENS IN SUBJECTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA WHO ARE NOT CONSIDERED CANDIDATES FOR HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL
02/13/2008 - 02/12/2010 (PI)
Millennium Pharmaceuticals, Inc.
54767414AMY300111/17/2017 - 11/17/2020 (PI)
Janssen Research and Development, LLC
Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …05/11/2015 - 05/31/2020 (PI)
Karmanos Cancer Center
PRONTO - Protocol NEOD001-20105/13/2016 - 05/31/2019 (PI)
Prothena Therapeutics Limited
DARA/JANSSEN PI Initiated03/28/2017 - 03/28/2019 (PI)
Janssen Scientific Affairs LLC
NEOD001-CL00209/24/2015 - 09/30/2018 (PI)
Prothena Therapeutics Limited
Secondary Analysis of Amyloid Repository Data09/15/2015 - 09/14/2017 (PI)
Prothena Therapeutics Limited